Vergote I, du Bois A, Floquet A, et al. - Researchers describe the final overall survival (OS) results of AGO-OVAR16 study, which was undertaken to test pazopanib for its efficacy, safety, and tolerability as maintenance therapy following first-line chemotherapy in patients with newly diagnosed advanced ovarian cancer (AOC). Using randomization (1:1), either 800 mg pazopanib once daily or placebo for up to 24 months, until disease progression, toxicity, withdrawal of consent, or death, was administered to 940 patients with histologically confirmed AOC, International Federation of Gynecology and Obstetrics stage II–IV. Progression-free survival prolongation was brought about by pazopanib but without improving the median OS. There were no new safety signals.